BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1640002)

  • 21. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
    Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
    Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of fluvastatin on human biliary lipids.
    Tazuma S; Ohya T; Mizuno T; Takizawa I; Kunita T; Takata K; Hayashi K; Hino F; Tokumo H; Watanabe T
    Am J Cardiol; 1995 Jul; 76(2):110A-113A. PubMed ID: 7604783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients.
    Holdaas H; Hagen E; Asberg A; Lund K; Hartman A; Vaidyanathan S; Prasad P; He YL; Yeh CM; Bigler H; Rouilly M; Denouel J
    Int J Clin Pharmacol Ther; 2006 Apr; 44(4):163-71. PubMed ID: 16625985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
    Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group.
    Jacotot B; Banga JD; Waite R; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):41A-46A. PubMed ID: 7604796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.
    Kivistö KT; Kantola T; Neuvonen PJ
    Br J Clin Pharmacol; 1998 Jul; 46(1):49-53. PubMed ID: 9690949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC.
    Siekmeier R; Lattke P; Mix C; Park JW; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):137-45. PubMed ID: 11509920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
    Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
    Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
    Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro.
    Rogler G; Lackner KJ; Schmitz G
    Am J Cardiol; 1995 Jul; 76(2):114A-116A. PubMed ID: 7604784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
    Eliav O; Schurr D; Pfister P; Friedlander Y; Leitersdorf E
    Am J Cardiol; 1995 Jul; 76(2):76A-79A. PubMed ID: 7604804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
    Reyderman L; Kosoglou T; Cutler DL; Maxwell S; Statkevich P
    Curr Med Res Opin; 2005 Aug; 21(8):1171-9. PubMed ID: 16083526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
    Smit JW; Jansen GH; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biotransformation of fluvastatin sodium in humans.
    Dain JG; Fu E; Gorski J; Nicoletti J; Scallen TJ
    Drug Metab Dispos; 1993; 21(4):567-72. PubMed ID: 8104114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of orally administered tizanidine in healthy volunteers.
    Tse FL; Jaffe JM; Bhuta S
    Fundam Clin Pharmacol; 1987; 1(6):479-88. PubMed ID: 3447935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Jejunal permeability and hepatic extraction of fluvastatin in humans.
    Lindahl A; Sandström R; Ungell AL; Abrahamsson B; Knutson TW; Knutson L; Lennernäs H
    Clin Pharmacol Ther; 1996 Nov; 60(5):493-503. PubMed ID: 8941022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.